DRUG	SUPPLIED	DOSE	COMMENTS
RITUXIMAB (Paeds) (Rituxan) Mechanism of action: Anti-CD20 monoclonal antibody. Ref: 44 Last update: 2022-04-23	injection: 100 mg/vial, 500 mg/vial	Children and adults: Refer to specific treatment protocol. The most common dosage regimen is 375 mg/m2/dose IV once weekly given by slow IV infusion. [Do not administer undiluted; do not administer as IV push or rapid IV infusion.]	Monoclonal antibody used to treat B cell lymphoma and post-transplant lymphoproliferative disease. Has also been used to treat chronic, steroid-resistant Graft Versus Host Disease (GVHD), autoimmune hemolytic anemia, chronic immune thrombocytopenic purpura. Infusion-related adverse effects include flu-like symptoms, fever, bronchospasm, hypotension, severe dyspnea, urticaria, angioedema and usually occur within 30-120 mins. Infusion-related adverse effects may occurup to 24 hrs after start of infusion. Premedication with analgesic, antihistamine and/or corticosteroids may help prevent infusion-related reactions. Other adverse effects may include neutropenia, lymphocytopenia, infections, hepatitis B and TB reactivation. Standard Prescription: rituximab __mg IV ___(frequency) (__mg/m2/dose)